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DNA Methylome of Familial Breast Cancer Identifies
Distinct Profiles Defined by Mutation Status
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Sunil Lakhani,3 Chris Boshoff,1 and Georgia Chenevix-Trench2
It is now understood that epigenetic alterations occur frequently in sporadic breast carcinogenesis, but little is known about the epige-
netic alterations associated with familial breast tumors. We performed genome-wide DNA-methylation proﬁling on familial breast
cancers (n ¼ 33) to identify patterns of methylation speciﬁc to the different mutation groups (BRCA1, BRCA2, and BRCAx) or intrinsic
subtypes of breast cancer (basal, luminal A, luminal B, HER2-ampliﬁed, and normal-like). We used methylated DNA immunoprecipita-
tion (MeDIP) on Affymetrix promoter chips to interrogate methylation proﬁles across 25,500 distinct transcripts. Using a support vector
machine classiﬁcation algorithm, we demonstrated that genome-wide methylation proﬁles predicted tumor mutation status with esti-
mated error rates of 19% (BRCA1), 31% (BRCA2), and 36% (BRCAx) but did not accurately predict the intrinsic subtypes deﬁned by gene
expression. Furthermore, using unsupervised hierarchical clustering, we identiﬁed a distinct subgroup of BRCAx tumors deﬁned by
methylation proﬁles. We validated these ﬁndings in the 33 tumors in the test set, as well as in an independent validation set of 47
formalin-ﬁxed, parafﬁn-embedded familial breast tumors, by pyrosequencing and Epityper. Finally, gene-expression proﬁling and
SNP CGH array previously performed on the same samples allowed full integration of methylation, gene-expression, and copy-number
data sets, revealing frequent hypermethylation of genes that also displayed loss of heterozygosity, as well as of genes that show copy-
number gains, providing a potential mechanism for expression dosage compensation. Together, these data show that methylation
proﬁles for familial breast cancers are deﬁned by the mutation status and are distinct from the intrinsic subtypes.Introduction
Breast cancer (MIM 11448) is one of the most common
cancers in the Western world, affecting one in ten women
during their lifetime.1 Mutations in the known breast can-
cer susceptibility genes, including BRCA1 (MIM 113705)
and BRCA2 (MIM 600185), account for approximately
only 25% of familial breast tumors.2 Expression proﬁling
has shown that breast cancers fall into ﬁve intrinsic sub-
types: luminal A, luminal B, HER2-ampliﬁed, basal, and
normal-like.3 Most BRCA1-related tumors are of the basal
subtype.4 However, we have shown that there is consider-
able heterogeneity among familial breast tumors, with
almost all ﬁve subtypes being found in each mutation
class.5
Epigenetic processes include DNA methylation, histone
modiﬁcations, chromatin structure, and noncoding RNA-
mediated regulation of gene expression.6 Historically,
DNA-methylation studies in cancer have revealed both
hypermethylation of promoter CpG islands and hypome-
thylation of repetitive DNA sequences.7 There are over
90 candidate genes reported throughout the literature as
promoter hypermethylated in breast cancers (Pubmeth
web resource). More recently, DNA-methylation alter-
ations have been studied in breast tumor tissue on a
genome-wide scale, revealing hypermethylated as well as
hypomethylated loci, compared to matched adjacent1CRUK Viral Oncology Group, UCL Cancer Institute, London WC1E 6BT, U
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tumors, ﬁve normal breast specimens, and several breast
cancer cell lines with Affymetrix promoter arrays and iden-
tiﬁed 2033 hypermethylated and 1473 hypomethylated
regions in the tumors, compared to the whole sections
of normal breast. Most of the differentially methylated
regions were recurrent, 90% of them occurring in at least
ﬁve tumors. Both the hyper- and hypomethylated regions
were also clustered in regions of long-range epigenetic
silencing (LRES)10 and were frequently found at gene
family clusters, including the proto-cadherin gene cluster
on chromosome 5.9,11 Ordway et al.8 evaluated nine inﬁl-
trating ductal breast carcinomas and matching normal
tissue with custom promoter-methylation microarrays
and identiﬁed 220 loci that distinguished tumor from
normal tissue. Five of these loci were validated in a series
of 230 clinical samples, and some showed considerable
promise as biomarkers.8 Promoter-tiling arrays have also
been used to evaluate a cell-line model of breast cancer
metastasis and have identiﬁed differential methylation in
genes involved in epithelial-mesenchymal transition and
tumor cell migration.12
One previous study suggested that hereditary breast
cancers have methylation similar to that of sporadic
tumors in ten candidate genes.13 However, a more recent
study investigated 11 candidate genes (ﬁve overlapping
with the previous study) and suggested that BRCA1-relatedK; 2Division of Genetics and Population Health, Queensland Institute of
gy, University of Queensland Centre for Clinical Research, University of
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breast cancers have less methylation than sporadic breast
cancers.14 To our knowledge, no study has yet performed
genome-wide methylation analysis on familial breast
cancers or looked for methylation differences between
familial breast tumor mutation classes. Therefore, we
sought to use genome-wide DNA-methylation proﬁling
of familial breast cancer cases to identify patterns of meth-
ylation speciﬁc to the different mutation groups (BRCA1,
BRCA2, non-BRCA1/2 [BRCAx]), which may provide clini-
cally relevant diagnostic value. The same tumor DNA
samples have been analyzed by gene-expression proﬁling
and copy-number analysis,5 allowing for the ﬁrst time
a comprehensive integrated genomic analysis of familial
breast tumors.Material and Methods
Patient Material
For DNA-methylation microarray analysis, we analyzed 33 fresh
frozen familial tumors, including BRCA1 (n ¼ 11), BRCA2 (n ¼ 8),
and BRCAx (n ¼ 14) tumors. Characteristics of these tumors have
been described in more detail elsewhere.5 The tumors were
collected by the Kathleen Cunningham Foundation for Research
into Breast Cancer (kConFab), a consortium which ascertains
multiple-case breast cancer families.15 Ethical approvals for
recruitment were obtained from the institutional review boards
or ethics committees at all of the sites. Written informed consent
was obtained from each participant. The BRCAx tumors came
from women from high-risk families ascertained by kConFab,
and in each case the tumor donor had undergone full BRCA1/2
mutation testing by full sequencing and multiplex ligation-
dependant probe ampliﬁcation. The additional validation set of
formalin-ﬁxed parafﬁn embedded (FFPE) tumors consisted of
BRCA1 (n ¼ 14), BRCA2 (n ¼ 13), and BRCAx (n ¼ 20) tumors
from kConFab. All specimens were evaluated by a pathologist for
percentage of neoplasia prior to DNA isolation and were selected
for DNA analyses if they were > 75% tumor after needle macrodis-
section. DNA was extracted by standard salt extraction and
phenol-chloroform protocol. Estrogen receptor (ESR1 [MIM
133430]), progesterone receptor (PGR [MIM 607311]), and HER2
(ERBB2 [MIM 164870]) status, grade, and tumor type were avail-
able from clinical records (Table S1, available online).
CGI Methylation Proﬁling
We performed microarray-based DNA-methylation analysis by
using methylated DNA immunoprecipitation (MeDIP) on high-
density Affymetrix tiling microarrays.16 MeDIP was performed
with the Diagenode MeDIP kit according to the manufacturer’s
protocol (Diagenode, Leige, Belgium). The Affymetrix GeneChip
Human Promoter 1.0R Array comprises over 4.6 million probes
tiled at an average resolution of 35 bp, covering approximately
10 kb around 25,500 transcription start sites (Affymetrix, High
Wycombe, UK). We performed triplicate MeDIP reactions for
each tumor and ampliﬁed them via whole-genome ampliﬁcation
with Genomiphi V2 according to the manufacturer’s protocol
(GE Healthcare). The triplicates were then pooled for one MeDIP
array and one input array per sample. The arrays were hybridized
with the use of Affymetrix hybridization reagents, with an Affy-
metrix hybridization oven, and stained and washed with the use
of the Fluidics Station 450 (Affymetrix, High Wycombe, UK).The AmeriArrays were scanned with the GeneChip Scanner 3000 7G with
autoloader. Raw data were extracted with the GeneChip Operating
System (GCOS) software from Affymetrix.qPCR Validation
Quality control of the MeDIP samples prior to microarray analysis
was performed via quantitative PCR (qPCR)-based analysis of
enrichment with the use of primers to ‘‘spiked in’’ and inherent
controls provided with the Diagenode MeDIP kit. These included
methylated sequence controls (human Alpha satellite and in vitro
methylated Arabidopsis DNA) and unmethylated controls (human
GAPDH promoter [MIM 138400] and unmethylated Arabidopsis
DNA). qPCR was performed with an Eppendorf realtime PCR
machine, and the reaction mix contained 13 SYBR green master
mix (Applied Biosystems, Foster City, USA) and 0.5 mM each of
forward and reverse primers in a volume of 30 mL. PCR cycling
consisted of 95C for 10 min, then 40 cycles of 95C for 30 s,
60C for 60 s, followed by a meltcurve analysis.Bisulphite Sequencing
We have used both pyrosequencing and Epityper-based analysis
for validation of DNA-methylation differences. Epityper was
used to cover long segments of DNA, covering up to 50 CpG sites
per gene. Pyrosequencing was used for shorter assays over higher-
density CpG regions (4–9 CpG sites). All primers used in this study
are presented in Table S2. DNA samples were bisulphite converted
with the EZ-96 DNAMethylation-Gold kit according to the manu-
facturer’s protocol (Zymo Research, Orange, CA).
Pyrosequencing
All pyrosequencing assays were designed with the PyroQ assay-
design software. A common tag was placed on either the forward
or the reverse primer (depending on the strand to be sequenced),
and a common universal biotinylated primer was used for all reac-
tions as previously described.17 PCR cycling conditions were per-
formed as previously described.18 All assays were optimized with
fully methylated gDNA (100%) (Zymo Research) compared to
unmethylated gDNA (0%, whole-genome ampliﬁed DNA [GE
Healthcare]). All products were conﬁrmed to be single bands by
agarose gel electrophoresis. Methylation values were calculated
as an average of all CpG sites within each assay as determined
by the Pyro Q-CpG software (Biotage, Uppsala, Sweden).
Epityper
Bisulphite-treated DNA (1 mL) was used in a 5 ml PCR reaction with
the use of 0.2 mM0T7-promoter-tagged reverse primer, 0.2 mM
10-mer-tagged forward primer, 1.5 mM MgCl2, 200 mM dNTP
mix, 13 FastStart Taq DNA Polymerase PCR Buffer (Roche Applied
Science, Penzberg, Germany), and 0.4 U FastStart Taq DNA poly-
merase (Roche Applied Science, Penzberg, Germany). The PCR
cycling conditions were 4 min at 94C, followed by 9 cycles of
94C for 20 s, 72C to 62C (1C per cycle) for 30 s, and 72C
for 1 min, followed by an additional 36 cycles at 62C annealing
temperature. Random products were visualized on a 1% agarose
gel to conﬁrm single-band ampliﬁcation. After Shrimp Alkaline
Phosphatase (SAP) treatment, PCR products were subjected to T
cleavage transcription and RNase A cleavage according to the Epi-
TYPER Application Guide (Sequenom, San Diego, CA), spotted
onto a SpectroCHIP array, and analyzed with the MassARRAY
Compact System MALDI-TOF mass spectrometer (Sequenom,
San Diego, CA). Data were analyzed with EpiTYPER software
(Sequenom, San Diego, CA). Primers were designed with EpiDe-
signer (Sequenom, San Diego, CA).can Journal of Human Genetics 86, 420–433, March 12, 2010 421
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Figure 1. DNA-Methylation Profiles of BRCA1, BRCA2, and BRCAx Tumors
(A) Percentage of genes that pass the FDR-corrected p value cutoff of p < 0.05 in an F-test testing for differences among mutation
subgroups (BRCA1 versus BRCA2 versus BRCAx) or for intrinsic subtypes (basal versus luminal A) across all genes. DNA-methylation
data (MeDIP) was compared to gene-expression microarray data (GEM) for all genes or was broken down into LCPs, ICPs, and HCPs
(see Figure S2). For mutation-status groups, the methylation proﬁles identiﬁed 822 signiﬁcant (FDR-corrected p < 0.05) genes (112,
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Statistical Analysis
DNA-Methylation Profiling with MeDIP Data
Raw data were analyzed with the MAT algorithm, which models
the baseline probe behavior and normalizes the probe t-value
score according to a probe-sequence-based model, taking into
account the MeDIP and input probe values.19 For transcription
start-site analysis, the MAT output t-values were combined for
each start site (obtained from USCS Genome Browser build 36)
5 250 bp around each start site (n ¼ 20527 unique transcripts).
These were subdivided into low-CpG-content promoters (LCPs,
n ¼ 5997), intermediate-CpG-content promoters (ICPs, n ¼
4544), and high-CpG-content promoters (HCPs, n ¼ 9986) as
previously described.16 In brief, HCPs (high-CpG promoters)
contain a CpG ratio above 0.75 and GC content above 55%,
LCPs (low-CpG promoters) contain a CpG ratio below 0.48, and
ICPs (intermediate-CpG promoters) are neither HCPs nor LCPs.
These were further ﬁltered to the genes that were represented by
both MeDIP and gene-expression data sets to 16237 genes
(LCPs, n ¼ 4738; ICPs, n ¼ 3517; HCPs, n ¼ 7982). Support vector
machine learning was performed with the MLInterfaces package.
In brief, the MLearn algorithm uses 5-fold balanced cross valida-
tion, using 80% of the data as a training set to predict the remain-
ing 20% of the data, through ﬁve iterations, resulting in a predic-
tion for each tumor in the data set. We used equal numbers of
tumors from each mutation group (n ¼ 8) or intrinsic subtype
(n ¼ 10) for each of the multiple iterations. The predictions pre-
sented are an average of ten permutations of sample selections
of the BRCA1 (8/11) and BRCAx (8/14) tumors compared to the
BRCA2 (8/8) tumors or basal (10/14) and luminal A (10/10)
tumors. Signiﬁcance of hierarchical clusters was calculated with
the R package ‘‘pvclust,’’ which computes an approximate unbi-
ased p value for clusters by using amultiscale bootstrap resampling
method.20 Pvclust was performed with n ¼ 1000 bootstrap with
all genes or with n ¼ 10,000 with ~1700 most-variable loci,
with similar results. Signiﬁcant clusters were identiﬁed with a
p value < 0.001. Gene set enrichment analysis (GSEA) was per-
formed as previously described via the preranked gene list
approach21. ‘‘Core enrichment’’ describes the leading edge of
the plot representing the genes that are most enriched. Autocor-
relation analysis (acf) was used for determining correlation
between neighboring genes to look for genome-wide evidence
of long-range epigenetic silencing. The frequency of high methyl-
ation in tumors (percentage of tumors with MeDIP t-value > 0.5)
was calculated for each gene, and all genes were ordered by their
chromosome location, such that each gene was next to its nearest
gene irrespective of the distance between them. Only one repre-
sentative transcription start site was used for genes with multiple
start sites.124, 586 for LCP, ICP, and HCP, respectively) compared to 47 signiﬁc
sion proﬁles. The signiﬁcant genes in the MeDIP proﬁles are biased
GEM proﬁles are not (p ¼ 0.517, chi-square test). For intrinsic subt
corrected p < 0.05) genes (606, 634, 1571 for LCP, ICP, and HCP, re
signiﬁcant (FDR-corrected p < 0.05) differences.
(B) Heatmap and clustering of 822 signiﬁcant (FDR-corrected p< 0.05
indicated on the right index—BRCA1 (red, n ¼ 11), BRCA2 (green, n
tumors compared to BRCA2 and BRCAx tumors. BRAC2 and BRCAx
shows the intrinsic subtypes basal (red, n¼ 14), luminal A (blue, n¼ 1
(gray, n ¼ 1).
(C) Bisulphite-sequencing analysis of RASSF1A, SGK1, LRRC55, LHCG
levels are indicated by the red line. Genomic locations for the region
Stars indicate statistically signiﬁcant differences between groups at p
(D) Validation of methylation differences in RASSF1A, SGK1, LRRC55
The AmeriPyrosequencing and Epityper Data
AWilcoxon signed rank sum test was used to determine statistical
signiﬁcance between groups for all pyrosequencing or Epityper
DNA-methylation data.Results
DNA-Methylation Proﬁles Are Deﬁned
by Mutation Status
In this study, we performed genome-wide DNA-methyla-
tion analysis by using MeDIP on Affymetrix human
promoter tiling arrays (1.0R) that cover over 25,500 indi-
vidual promoters. We assayed 33 familial breast tumors
(11 with BRCA1 mutations, 8 with BRCA2 mutations,
and 14 from non-BRCA1/2 families [BRCAx]) to investigate
the contribution of mutation status to the tumor DNA-
methylation proﬁle. These tumors have also been proﬁled
with the Illumina gene expression and SNP-CGH array for
copy numbers, thus allowing comparisons across all three
platforms on the same samples.5 Tumor information,
including hormone receptor status, stage, and intrinsic
phenotypic subtype, is provided in Table S1. Validation
of MeDIP enrichment before and after ampliﬁcation was
performed via qPCR for methylated and unmethylated
controls, and the correlation between MeDIP t-value and
methylation percentage was assessed by pyrosequencing
for four genes: DHX33 (methylated [GeneID: 56919]),
GRHL2 (unmethylated [MIM 608576]), IGF2 DMR0 (im-
printed [MIM 147470]), and RASSF1A (frequently methyl-
ated in breast cancer [MIM 605082]) (Figure S1). These
controls show good correlation between the absolute
methylation percentage and the average MeDIP t-values
provided by themicroarray (R2> 0.5, p< 0.0001). Interest-
ingly, 15 of 33 tumors (45%) showed loss of imprinting
(LOI) at IGF2 DMR0 with the use of a previously reported
cutoff of < 35% methylation for sporadic breast cancers.22
Both gene-expression and DNA-methylation proﬁles
were analyzed to identify the number of genes that could
differentiate the mutation subgroups or the intrinsic sub-
types (Figure 1A). For mutation-status groups, with com-
parison of BRCA1 tumors to BRCA2 and BRCAx tumors,
the methylation proﬁles identiﬁed 822 signiﬁcant genes
(false discovery rate [FDR]-corrected p < 0.05, F-test),
compared to only 47 signiﬁcant (FDR-corrected p < 0.05,ant (FDR-corrected p < 0.05) genes (11,13, 23) in the gene-expres-
toward the HCPs (p ¼ 7.15 3 1037, chi-square test), whereas the
ypes, the gene-expression proﬁles identify 2811 signiﬁcant (FDR-
spectively), whereas the methylation proﬁles did not identify any
) differences between 33 tumors representing mutation subgroups
¼ 8), and BRCAx (blue, n ¼ 14)—reveal a distinct cluster of BRCA1
tumors do not divide into separate clusters. The index on the left
0), luminal B (green, n¼ 4), HER2 (yellow, n¼ 4), and normal-like
R, and PKD2 in 33 fresh frozen tumors. The median methylation
s presented are from UCSC human March 2006 assembly (hg18).
< 0.05 and p < 0.01 as indicated (Wilcoxon signed-rank sum test).
, LHCGR, and PKD2 in the 47 FFPE breast tumor DNA samples.
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Table 1. Genome-wide Methylation Profiles Predict Mutation Status, and Gene-Expression Profiles Predict Intrinsic Subtype
MeDIP Predicted
Given BRCA1 BRCA2 BRCAx Error (%) Predicted (%) Expected (%) Gain (%)
BRCA1 6.5 0.6 1.2 18.8 81.3 33.3 47.9
BRCA2 0.8 5.5 1.7 31.3 68.8 33.3 35.4
BRCAx 0.8 2.7 5.1 36.3 63.8 33.3 30.4
MeDIP Predicted
Given Basal LumA Error (%) Predicted (%) Expected (%) Gain (%)
Basal 5.8 4.3 42.0 58.0 50.0 8.0
LumA 5 5.1 49.0 51.0 50.0 1.0
GEM Predicted
Given BRCA1 BRCA2 BRCAx Error (%) Predicted (%) Expected (%) Gain (%)
BRCA1 7.1 0.9 0 11.3 88.8 33.3 55.4
BRCA2 0.3 4.5 3.2 43.8 56.3 33.3 22.9
BRCAx 1.9 3.8 2.3 71.3 28.8 33.3 4.6
GEM Predicted
Given Basal LumA Error (%) Predicted (%) Expected (%) Gain (%)
Basal 10 0 0.0 100.0 50.0 50.0
LumA 0 10 0.0 100.0 50.0 50.0
Support vector machine learning prediction of mutation status or intrinsic subtype based onmethylation profiles (MeDIP) or gene-expression profiles (GEM). Anal-
ysis of MeDIP data was performed on a random selection of 24 tumors (eight from each group), and the numbers presented are an average of ten permutations of
sample selections, such that all tumors were used in the analysis. These numbers do not always add up to 8, as a result of the averaging across the ten permu-
tations. GEM analysis was performed on a random selection of 20 tumors (ten from each group), and the numbers presented are an average of ten permutations of
sample selections, such that all tumors were used in the analysis. Analysis could be performed only on the two largest groups (basal and luminal A). Gain
percentage represents the improvement of the prediction over random chance (percentage expected).F-test) genes identiﬁed in the gene-expression proﬁles.
When these data were broken down to promoter classes
on the basis of the CpG ratio (deﬁned previously16 and
in Material and Methods; Figure S2), we observed that
high-density CpG island promoters contribute most to
the differences among mutation groups (p ¼ 7.15 3
1037, chi-square test), whereas gene-expression proﬁles,
on the other hand (with only 47 signiﬁcant genes), were
not biased (p ¼ 0.517, chi-square test). In contrast to the
mutation groups, analysis of intrinsic subtypes identiﬁed
2811 genes that were signiﬁcantly different (FDR-corrected
p < 0.05, F-test) in the gene-expression proﬁles between
basal and luminal A breast tumors, but the MeDIP methyl-
ation proﬁles did not identify any signiﬁcant (FDR-cor-
rected p < 0.05) differences between basal or luminal
breast tumors.
We further validated this ﬁnding by using a support
vector machine (svm) classiﬁcation algorithm to predict
the mutation status or intrinsic subtype on the basis of
either the gene-expression proﬁles or the MeDIP methyla-
tion proﬁles (Table 1). This algorithm contains a balanced
5-fold cross-validation system, which uses 80% of the data
as a training set to predict the remaining 20% of the data,
through ﬁve iterations, resulting in a prediction for each
tumor in the data set. As expected, gene-expression data424 The American Journal of Human Genetics 86, 420–433, March 1correctly predicts intrinsic subtype with 100% accuracy,
and it predicts BRCA1 mutation with 90% accuracy,
mainly because of the fact that BRCA1 tumors are also
predominantly basal tumors. The GEM also predicts
BRCA2 tumors correctly 55% of the time. However, the
gene-expression proﬁles fail to predict BRCAx tumors.
This is consistent with previous studies.23 Conversely,
the MeDIP methylation proﬁles fail to predict the intrinsic
subtypes, but prediction of mutation classes is improved
by consideration of MeDIP methylation proﬁles. Methyla-
tion pattern predicted BRCA1, BRCA2, and BRCAx tumors
with estimated error rates of 19%, 31%, and 36%, respec-
tively, which is more accurate than the prediction error
rates from gene-expression proﬁles (11%, 44%, 71% for
BRCA1, BRCA2, and BRCAx, respectively). The most inter-
esting improvement is themarked increase in prediction of
BRCAx tumors: from 71% error with gene-expression
proﬁling (more than would be expected by chance; 66%
error), down to 36% with methylation proﬁling. This can
be also represented as the percentage gain that is the
improvement of the prediction over random chance
(percentage expected), which shows a 30% gain for
MeDIP prediction of BRCAx in comparison to the 4.5%
loss of prediction over random chance for gene-expression
predictions.2, 2010
Hierarchical clustering of promoter methylation pat-
terns of the 822 genes that deﬁned the mutation groups
shows a distinct group of BRCA1 tumors and a less-deﬁned
cluster of BRCA2 and BRCAx tumors (Figure 1B). We per-
formed pyrosequencing-based and MALDI-TOF-based
(Epityper) methylation analysis for eight of these genes,
including one frequently hypermethylated gene, RASSF1A,
and seven additional genes (SGK1 [MIM 602958], LRRC55
[GeneID: 219527], LHCGR [MIM 152790], PKD2 [MIM
173910], GRAMD1C [GeneID: 54762], DA103059 [hypo-
thetical], and HTR6 [MIM 601109]) in the 33 frozen tumor
samples from the test set. These genes were picked from
the list of 822 genes that deﬁned the mutation groups.
Five of these eight genes (RASSF1A, SGK1, LRRC55, LHCGR,
and PKD2) showed statistically signiﬁcant differences
between mutation groups in the original test set (n ¼ 33)
(Figure 1C) and, even more so, in the validation set of
FFPE tumors (n ¼ 47) (Figure 1D). The only genes that
were not validated in the FFPE tumor panel were
GRAMD1C, DA103059, and HTR6 (Figure S3). The LHCGR
gene was analyzed by both pyrosequencing and Epityper,
with good correlation over the overlapping sequence
(r2 ¼ 0.689, p < 0.0001).DNA-Methylation Proﬁles Deﬁne BRCAx Subgroups
Given that BRCA1 breast tumors showed a speciﬁc methyl-
ation proﬁle, we examined the methylation patterns in
BRCAx tumors to determine whether subgroups could be
delineated that might reﬂect germline mutations in the
same genes or pathways. Using unsupervised hierarchical
clustering of the 14 BRCAx tumor samples across all
16237 genes with a multiscale bootstrap resampling, we
identiﬁed a subgroup of ﬁve tumors that signiﬁcantly clus-
tered together (p < 0.0001) (Figures 2A and 2B). These ﬁve
tumors included two basal tumors, two luminal A tumors,
and one luminal B tumor, suggesting that this cluster is
not deﬁned by the intrinsic subtypes. We identiﬁed 156
genes that signiﬁcantly differentiate this group, designated
BRCAx-a, from the remaining nine tumors, which are
designated BRCAx-b (Table S3). We validated three of these
genes, HTR6, LHCGR, and GEMIN8 (GeneID: 54960), in
both tumor panels (Figures 2C and 2D). In the fresh frozen
tumor panel (n ¼ 33), we observed a signiﬁcant increased
methylation in the BRCAx-b group (median methylation
of 47.9%) as compared to the BRCAx-a group (12.3%)
(p ¼ 0.016, t test) in the promoter CpG island of the
LHCGR gene. In the HTR6 gene, we observed regions of
signiﬁcantly higher methylation in the BRCAx-b group
(57.8%) as compared to the BRCAx-a group (34.5%). In
GEMIN8, we observed signiﬁcantly increased methylation
in the BRCAx-a group (15.9%) as compared to the
BRCAx-b group (6.5%). We were unable to clearly deﬁne
two subgroups in the FFPE tumor panel (n ¼ 47) on the
basis of these three genes alone; however, we did observe
bimodal distribution of methylation in each of these genes
potentially indicative of different groups (Figure 2D).The AmeriValidation of Previous Findings in Sporadic
Breast Cancer
Until recently, the majority of DNA-methylation studies
have identiﬁed individual genes or small sets of candidate
genes that are hypermethylated in breast cancers with
varying frequencies. With our genome-wide data, we
were able to validate previous ﬁndings such as hyperme-
thylation of various candidate genes in breast cancer and
regions of long-range epigenetic silencing (LRES) and to
perform ﬁne mapping of regions of hypermethylation.
Using gene set enrichment analysis, we investigated
a list of genes that were previously identiﬁed as hyperme-
thylated in breast cancer in greater than 20% of tumors
and that were also represented on the microarray (n ¼ 72
(Figures 3A and 3B, Table S4). The reported hypermethy-
lated genes are indeed enriched in the MeDIP microarray
analysis (p ¼ 0.042), and we identiﬁed 38 genes in the
core enrichment that are most frequently methylated in
the familial breast cancers (Table S4), with the strongest
enrichment in BRCA1 tumors (p ¼ 0.044). We identiﬁed
the genes, including HRAS (MIM 190020), CXCL1 (MIM
155730), GREM1 (MIM 603054), CDCP1 (MIM 611735),
and RB1 (MIM 180200), from this list that signiﬁcantly dif-
ferentiate the mutation subgroups (Figures 3C and 3D),
and we have presented detailed Epityper-based validation
of the Gremlin 1 gene (GREM1) (Figure 3E). In this gene,
we observed higher methylation in the BRCA2 (median
methylation 30.8%) and BRCAx (25.8%) tumors as com-
pared to the BRCA1 tumors (19.9%).
LRES has been reported previously in sporadic breast
cancer and in colorectal cancer (MIM 114500) and suggests
that there may be a relationship between frequently meth-
ylated genes in gene family clusters or on nearby chromo-
somal locations.9,11 We used an autocorrelation analysis to
look for genome-wide evidence of LRES in familial breast
tumors. We show that there are over 1500 genes that are
frequently methylated (MeDIP t-value > 0.5) in more
than 30% of tumors (n ¼ 33; Figure 4A) and that there is
a statistically signiﬁcant autocorrelation between any
gene and up to three of its nearest neighbors (Figure 4B).
The high-density array allows for ﬁne mapping of DNA-
methylation differences with the use of a probe-wise anal-
ysis, and we have used this approach to validate ESR1 (ERa)
methylation. Previous studies have shown that ﬁve indi-
vidual CpG dinucleotides in the ESR1 promoter were
more methylated in BRCA1 tumors as compared to ER-
negative tumors and have suggested that this may be an
important factor in transcriptional repression of this
gene in BRCA1-linked breast cancers.24 We have mapped
the critical region of hypermethylation in BRCA1-linked
ER-negative tumors to a 147 bp region (region 2) of the
CpG island containing 20 CpG sites (chr6:152171256–
152171402; NCBI build 36.1) (Figure S4). We further vali-
dated this in our samples by using pyrosequencing,
showingmedian methylation of 10.6% in BRCA1 ER-nega-
tive tumors, as compared to 7.5% in the other ER-negative
tumors (p ¼ 0.0056).can Journal of Human Genetics 86, 420–433, March 12, 2010 425
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Figure 2. Methylation Profiling Reveals a Distinct Subgroup of BRCAx Tumors
(A) Unsupervised heirarchical clustering of the 14 BRCAx tumor samples across all 16237 genes usingmultiscale bootstrap resampling to
generate p values for clusters (pvclust). Clusters with p< 0.0001 are boxed in red. Samples are labeledwith their intrinsic subtype to show
that the groupings are not related to the tumor phenotype.
(B) Heatmap and clustering of 156 signiﬁcant (p.fdr < 0.05) differences between the BRCAx-a subgroup (dark blue) compared to the re-
maining tumors (pale blue, termed BRCAx-b) shows that the majority of differences (136/156) are increases in methylation in BRCAx-b.
The full list of genes is presented in Table S2.
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Integration of Methylation, Copy-Number,
and Gene-Expression Data
This data set represents, to our knowledge, the ﬁrst fully
integrated analysis of familial breast tumors with genome-
wide DNA-methylation, copy-number, and gene-expres-
sion data. For each tumor, every gene was scored as over-
lapping with regions of homozygous deletion (HD), loss
of heterozygosity (LOH), copy-neutral LOH, copy gains
(GAIN), or no change (diploid) in that tumor. For each
gene, the median MeDIP t-value was then calculated
from tumors in each of the ﬁve copy-number groups (if
present) with the use of the diploid tumors as a reference
level for that gene (Figure 5). Hierarchical clustering iden-
tiﬁed two groups of genes, the ﬁrst containing both LOH
and high methylation in tumors and the second contain-
ing copy-number gains and high methylation in tumors
(Figure 5A). This was observed in 607/4921 (12.3%) genes
with LOH and in 1032/9070 (11.4%) genes with copy-
number gains. In contrast, the methylation of genes in
copy-neutral LOH regions was higher than in diploid
tumors for only 129/15213 (0.8%) genes. This is statisti-
cally supported by chi-squared analysis (c2 ¼ 407.2, p <
2.2 3 106) (Table S5). Similar results were obtained
when tumors were separated into mutation groups (Fig-
ure S5). Furthermore, the median methylation (t-values)
for all genes with LOH was 0.72 (range 0.5–4.0) and copy
gain was 0.70 (range 0.5–6.3), both of which were signiﬁ-
cantly higher than that of copy-neutral LOH genes, which
had a median of 0.60 (range 0.5–1.3) (Figure 5B). Gene
expression of these groups shows that genes within regions
of LOH and high methylation more often have decreased
expression (p ¼ 0.00022) and that genes within regions
of copy gain often maintain higher expression (p ¼ 1.7 3
105), albeit a very modest median increase: 0.08 (log2 D
gene expression) (Figure 5C).Discussion
Hypermethylation of promoter CpG islands occurs
frequently in numerous genes in almost all human
cancers.25 Genome-wide hypomethylation is also fre-
quently observed in tumor cells compared to normal
tissue.25 Which, if any, of these frequent epigenetic
changes are early ‘‘driving’’ epimutations or late-event
‘‘passenger’’ epimutations is not clear, nor is the mecha-
nism of how these alterations occur known. In this study,
we have shown that different germline mutations can lead
to very different epigenetic proﬁles in breast tumors. Meth-
ylation markers might therefore be useful as an additional
tool for predicting mutation status of tumors, prior to(C) Bisulphite sequencing validation of GEMIN8, HTR6 and LHCG
median methylation levels are indicated by the red line. Genomic
Assembly (hg18). Stars indicate statistically signiﬁcant differences bet
rank sum test.
(D) Validation of methylation differences in GEMIN8, HTR6 and LH
samples. Distribution histograms are presented below to show the b
The Americonﬁrmation by sequence analysis, and for distinguishing
pathogenic from neutral variants in BRCA1.26,27
An epigenetic role for BRCA1 has been proposed because
of its binding to HDAC1 (MIM 601241) and HDAC2 (MIM
601241) and chromatin-remodelling complexes.28,29
However, a direct role for BRCA1 in DNA methylation
has not yet been investigated. There are conﬂicting reports
about the level of methylation in BRCA1-mutated tumors
compared to sporadic breast tumors.13,14 We showed
that the BRCA1 tumors have the most distinct genome-
wide DNA-methylation proﬁles with the highest svml
predictions and the most signiﬁcant clustering. In the
genes that we have validated in both sets of tumors (e.g.,
RASSF1A, SGK1, HTR6, LHCGR, PKD2, and others), we
observed lower methylation levels in the BRCA1 breast
tumors compared to the BRCA2 and BRCAx tumors. Low
levels of methylation have been observed in other genes
in BRCA1 tumors, best exempliﬁed by HIN1 (SCGB3A1
[MIM 606500]).13,14,30,31 Together, these data are consis-
tent with a role for BRCA1, direct or indirect, in de novo
methylation of these genes or in the spreading and main-
tenance of methylation marks, a function that is likely to
be absent in BRCA1-mutated tumors. Therefore, further
investigation of the role of BRCA1 in DNA methylation
is warranted. Recently, DNA demethylation has been
shown to be cyclical in the estrogen-responsive promoters
dependant on deamination and glycosylation and on base-
excision-repair pathways, suggesting a rapidly changing
DNA-methylation state.32,33 There is now compelling
evidence that DNA demethylation involves DNA repair
via a 5-meC deaminase, activation-induced deaminase
(AICDA [MIM 605257]), and a G:T mismatch-speciﬁc
thymine glycosylase, Mbd4 (MIM 603574), and is pro-
moted by GADD45 (MIM 126335) proteins through phys-
ical interactions with both AICDA and Mbd4.34,35 These
data suggest that the enzymatic reaction maintaining the
DNA methylation is in a ﬁne balance that can be shifted
rapidly and that fully functional DNA repair pathways
are required. Interestingly, although BRCA1 transactivates
GADD45 promoter in response to DNA damage, it has
been reported to repress GADD45 transcription in unper-
turbed cells through interaction with CtIP (RBBP8 [MIM
604124]), a corepressor.36 Thus, it is possible that increased
GADD45 expression in the absence of BRCA1may account
for hypomethylation seen in BRCA1 tumors compared to
other familial tumors.
Gene-expression proﬁling of sporadic and familial breast
tumors can categorize them into deﬁned pathological
and clinically different intrinsic subtypes, including basal
tumors (often triple-negative, BRCA1-mutated tumors and
poorer prognosis), HER2-ampliﬁed tumors, and luminalR comparing BRCAx-a subgroup to the BRCAx-b subgroup. The
locations for the regions presented are from Human Mar. 2006
ween groups at p< 0.05 and p< 0.01 as indicated, wilcoxon signed
CGR in 47 formalin ﬁxed parafﬁn embedded breast tumor DNA
imodal distribution of methylation for these genes.
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Figure 3. Validation of Previously Identified Hypermethylated Genes in Breast Cancer
(A) GSEA comparing a list of genes that are commonly hypermethylated in breast cancers (n ¼ 72) to the 16237 genes preranked on
MeDIP t-values averaged across all tumors (black line), or separated into BRCA1 (red), BRCA2 (green), or BRCAx (blue) tumors.
The nominal p value estimates the statistical signiﬁcance of the enrichment score for a single gene set using a random permutation
of the gene list.
428 The American Journal of Human Genetics 86, 420–433, March 12, 2010
A
Histogram of freq
y
3
0
0
0
4
0
0
0
F
re
q
u
e
n
c
y
0
1
0
0
0
2
0
0
0
freq
0 10 20 30 40 50 60 70
0
Autocorrelation
B
0
0
.1
5
0
.2
0
F
0
.0
0
0
.0
5
0
.1
0
A
C
F
0 2 4 6 8 10
Lag
Figure 4. Autocorrelation between Frequently Methylated
Genes in Familial Breast Cancer
(A) Histogram of the frequency of methylation in tumors
(percentage of tumors with MeDIP t-value > 0.5) across all unique
genes, showing 1581 genes methylated in > 30% of tumors.
(B) All genes were ordered by their chromosome location, such
that each gene was next to its nearest gene. Only one representa-
tive transcription start site was used for genes with multiple start
sites. Autocorrelation analysis of the frequencies of methylation
for each gene shows increased autocorrelation (>95% conﬁdence
interval, blue dotted line) between any gene and its next three
neighboring genes, showing evidence for LRES in clusters up to
four genes.tumors (hormone-receptor positive and better prog-
nosis).3,5 In this study, we have attempted to use the
DNA-methylation proﬁles to recapitulate the clustering
into these intrinsic subtypes. However, we observed no
signiﬁcantly different genes between the basal and luminal
groupings; thus, it is not surprising that the svml predic-(B) GSEA of all breast tumors (black line in Figure 4A) showing each of
ment (p ¼ 0.042) of the hypermethylated genes across the whole data
among the frequently methylated genes (core hypermethylated gen
(C) t test for intergroup analyses comparing BRCA1 to BRCA2, BRCA2
above 1.3 (p ¼ 0.05) indicate signiﬁcant differences in methylation
(D) Representative examples of genes that differentiate tumors on the
whisker plots representingmedian (center line), interquartile range (b
are represented as points.
(E) Epityper validation of GREM1 comparing 33 familial breast tumo
(green, n ¼ 8), and BRCAx (blue, n ¼ 14). Presented is the mean m
(5 SEM). The line between sites indicates contiguous CpG sites. Gen
March 2006 assembly (hg18).
The Ameritions using the methylation proﬁles were unable to iden-
tify whether the tumors were basal or luminal breast
tumors. We do not discount the possibility that larger
numbers of tumors may identify statistically signiﬁcant
differences between intrinsic subtypes. Given that BRCA1
tumors were accurately predicted and that almost all
BRCA1 tumors are basal tumors, one might assume that
the methylation proﬁling should have predicted the basal
tumors. However, there were an additional four basal
tumors that were BRCAx tumors, and these tumors had
methylation proﬁles very different from those of the
BRCA1 tumors, which accounts for the poor prediction
of basal tumors. These data suggest that the differences
in gene expression that deﬁne these intrinsic subgroups
are not regulated by differential DNA methylation.
We have recently shown by gene-expression proﬁling
that, like sporadic tumors, BRCAx tumors are heteroge-
neous and manifest all ﬁve intrinsic subtypes.5 However,
we have found that DNA-methylation proﬁling predicted
a higher number of BRCAx tumors, with 64% accuracy,
than did gene-expression data (29% accuracy). Further-
more, when we performed unsupervised hierarchical clus-
tering on these samples, we found a subset of tumors that
clustered together in a highly signiﬁcant branch of the
cluster (p < 0.0001). These ﬁve tumors included two basal,
two luminal, and one HER2 tumor, indicating that these
groupings are not reliant on the intrinsic subtypes. Given
that the BRCA1 tumors, all of which harbor mutations in
the same gene, have a distinctive methylation proﬁle, we
hypothesize that this subgroup of BRCAx tumors with
similar proﬁles may harbor mutations in the same gene
or same pathway. The methylation of genes such as
HTR6, LHCGR, and GEMIN8, in which we have validated
the differences in these groups, may be used in future
studies to subdivide this heterogeneous tumor group
into a subclass that may be more homogenous and
may increase the sensitivity of linkage analysis or high-
throughput-sequencing mutation screening for the identi-
ﬁcation of breast cancer susceptibility genes. However, we
note that only 14 BRCAx tumors were proﬁled in this
study. Although validation in the 47 FFPE tumors showed
bimodal distribution of methylation for these genes, the
existence of BRCAx subtypes with different methylation
proﬁles needs to be further validated with a larger panel
of genes in more BRCAx tumors, including sets from
within the same family, in order to determine whetherthe 72 genes represented by black bars. This analysis shows enrich-
set, with a core set of 38 genes signiﬁcantly enriched (p < 0.0001)
es; Table S3).
to BRCAx, or BRCAx to BRCA1, presented aslog(10) p values. Bars
among the groups for 28 of these genes.
basis of mutation status. MeDIP t-values are presented as box and
ox), and 95th percentiles (whisker), and samples outside this range
rs representing mutation subgroups BRCA1 (red, n ¼ 11), BRCA2
ethylation at each CpG site (or CpG cluster) across the amplicon
omic location for the region presented is from the UCSC human
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Figure 5. Copy Number versus Methylation Reveals Frequent Methylation in Tumors with LOH or Copy-Number Gains
(A) Heatmap of median methylation levels (MeDIP t-values) for each copy-number group. For each gene (n ¼ 16237), tumors were
broken down into copy-number groups (y axis) of tumors showing homozygous deletion (HD, n ¼ 653), loss of heterozygosity
(LOH, n ¼ 4921), normal diploidy (n ¼ 16237), copy-neutral LOH (n ¼ 15213), or gains (n ¼ 9070). This shows 607 (12.3%) genes
with increased methylation in the tumors that show LOH compared to the normal diploid tumors and 1032 (11.4%) genes with
increased methylation in the tumors that show copy-number gains compared to diploid tumors. The methylation of genes in copy-
neutral LOH regions was not signiﬁcantly different from that of diploid tumors, with only 123 genes with increased methylation
(0.8%). Blue, increased methylation; yellow, decreased methylation.
(B) Box plot of median methylation levels (y axis, MeDIP t-values) for the genes that have LOH and increased methylation (compared to
diploid tumors), copy-neutral LOH and increased methylation, or copy-number gains and increased methylation. This analysis shows
a wider range of increased methylation in the LOH and GAIN tumors compared to the neutral LOH genes.
(C) Gene-expression analysis (log-fold change) of the same genes shown as a box plot of difference inmedian expression levels of diploid
tumors compared to LOH tumors, copy-neutral tumors, or copy-gain tumors. This shows that tumors containing LOH and methylation
more often have decreased expression and that copy-gain tumors often maintain higher expression.there might be a genetic basis to such methylation
subtypes.
The genome-wide nature of our methylation analysis
has allowed us to investigate the methylation of any
gene with high probe-level resolution (~35 bp resolution).
We used this resolution to validate the ﬁne mapping of
increased methylation changes in the ﬁrst intron of the
ESR1 gene in BRCA1 tumors compared to non-BRCA1
tumors.24 This has been proposed as one speciﬁc mecha-
nism by which BRCA1 tumors alter ESR1 expression,
thereby altering the response to antiestrogen therapies,
and may account for a difference between BRCA1 and
non-BRCA1 basal tumors.24,37 BRCA1 is also recruited to
the ESR1 promoter by Oct1, where it is required for ESR1
expression.38 It is not yet known whether this binding of430 The American Journal of Human Genetics 86, 420–433, March 1BRCA1 to the promoter is responsible for the change in
CpG island methylation.
We performed validation of variable methylation levels
in numerous genes, including RASSF1A, SGK1, PKD2,
HTR6, LHCGR, andGEMIN8. We hypothesize that differen-
tial methylation of these genes may contribute to phe-
notypic differences among these mutation classes. For
example, we observed increased methylation of the lutei-
nizing hormone/choriogonadotropin receptor (LHCGR)
in BRCA2 and BRCAx compared to BRCA1 tumors. This
gene is regulated by DNAmethylation and histone modiﬁ-
cations, and its mRNA is undetectable in up to 65% of
unselected breast cancers.39,40 Furthermore, the expression
of LHCGR is increased in more invasive breast tumors;
thus, the decreased methylation of LHCGR that we2, 2010
observed in BRCA1 tumors may contribute to their
increased aggressiveness as compared to other tumors.41,42
PKD2 is a membrane-bound protein involved in tubulo-
genesis.43 Increased methylation of PKD2 in BRCA2-
related breast tumors may, therefore, promote the
increased tubular or tubulo-lobular morphology observed
in BRCA2 tumors compared to other tumors.44 The serum-
and glucocorticoid-inducible kinase 1 (SGK1) is a serine/
threonine protein kinase that is involved in cellular stress
and may have an important role in breast tumor aggres-
siveness.45 Furthermore, it is induced in a p53-dependent
manner after DNA damage and is activated by the mTOR
pathway.46,47 Our ﬁnding that SGK1 is less methylated in
BRCA1-mutated tumors is consistent with the increased
activity of the mTOR signaling pathway observed in
basal-like breast cancers.42,48 Further investigation of the
role of methylation of these genes in breast carcinogenesis
is warranted.
We have generated, for the ﬁrst time, a complete data set
of DNA-methylation, gene-expression, and copy-number
variation on 33 familial breast tumors covering 16237
gene transcripts (freely available resource; GEO accession
no. GSE17125). We did not observe a strong genome-
wide correlation between gene expression and methyla-
tion. This is not surprising, given that themajority of genes
have unmethylated promoters despite differential gene
expression regulated by transcription factors and other
regulatory mechanisms. However, we could identify ~800
genes in which gene expression was signiﬁcantly inversely
correlated with DNA methylation (Table S5). We did
observe a strong relationship between methylation and
copy number, a signiﬁcant number of genes showing
both LOH and increased methylation, which suggests
that these genes conform to the Knudson two-hit hypoth-
esis for tumor-suppressor genes.49 In addition, we observed
a large number of genes that show copy-number gain and
increased methylation, which we hypothesize may be a
mechanism for dosage compensation to reduce the level
of expression of ampliﬁed genes.
In summary,wehave shown thatmethylationproﬁles for
familial breast cancers are deﬁned by the mutation status
and are distinct from the intrinsic subtypes. This ﬁnding
requires independent conﬁrmation in a larger panel of
familial tumors. Finally, we have provided a novel resource
integrating genomic analysis of DNA-methylation, gene-
expression, and copy-number changes that will be useful
for future genomic research in familial breast cancers.Supplemental Data
Supplemental Data include ﬁve ﬁgures and six tables and can be
found with this article online at http://www.ajhg.org.Acknowledgments
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